Funding for this research was provided by:
Instituto de Salud Carlos III (Red de Terapia Celular (RETIC TerCel, RD16/0011/0003, 0005, 0015;, PIC18/00001))
Consejería de Educación, Junta de Castilla y León (Centro en Red de Medicina Regenerativa, Escalera de Excelencia CLU-2019-02))
Received: 8 November 2021
Accepted: 22 November 2021
First Online: 11 December 2021
: All the procedures of the original clinical trials were approved by the Institutional Review Boards of the corresponding Hospitals and by the Spanish Agency of Medicines and Medical Devices.
: Not applicable.
: J.G.S. is member of the Board of Directors of Citospin, a spin-off company of the University of Valladolid (Spain) that specializes in GMP-compliant cell production. M.A. and V.G. are employees of Citospin. The other authors declare that they have no conflicts of interest.